HDAC Inhibitors as Epigenetic Regulators

Alterations in the volume of T2 lesion were more variable and did not reach statistical significance for the population as a whole. (12. 8 vs 7. a few months), there was no significant difference in overall survival between the two populations (17. 0 vs 17. 8 months). The median contrast-enhancing lesion volumes decreased from 6. 3 to 1. 9 cm3from baseline to the postradiotherapy scan for patients in the TMZ+enza cohort and from 2 . 8 to 0. 9cm3for the TMZ+erl+bev cohort. Changes in the T2 lesion volumes were only significant intended for the latter cohort (26. 5 to 11. 9 cm3). The median apparent diffusion coefficient and related diffusion parameters were significantly increased for the TMZ+enza cohort (1054 to 1225 m2/s). More of the anatomic parameters were associated with survival for the TMZ+enza cohort, whereas more diffusion parameters were associated with survival intended for the TMZ+erl+bev cohort. SUMMARY: The early changes in anatomic and diffusion imaging parameters and their association with survival reflected differences in the mechanisms of action of the treatments that were being given. This suggests that integrating diffusion metrics and anatomic lesion volumes into the Response Assessment in Neuro-Oncology criteria would assist in interpreting treatment-induced changes and predicting outcome in patients with newly diagnosed glioblastoma who are receiving such combination treatments. == Introduction == Glioblastoma (GBM) is the most malignant primary malignant brain tumor in adults. The standard of care for patients with newly diagnosed GBM consists of surgery, radiotherapy (RT), and temozolomide (TMZ). In a recent phase III trial, patients treated in this manner had significantly improved overall survival (OS) compared with patients who received RT only[1]. The median overall survival obtained with this treatment was 15 months[1]. A number of different therapeutic brokers that are expected to have a synergistic effect with RT and TMZ have been considered[2],[3],[4],[5],[6], with the goal of improving results for patients with GBM. Assessment of early response to these combination treatments is complicated by their different mechanisms of action and the impact that they have on standard magnetic resonance (MR) imaging parameters[7]. HDAC2 Enzastaurin is a protein kinase C -inhibitor that is reported as having a direct Gabazine antitumor effect through the suppression of tumor cell proliferation and induction of apoptosis, and indirect effects that are expressed by the inhibition of tumor-induced angiogenesis[8]. Preclinical reports have shown that it is synergistic with radiation and induces apoptosis in glioma model systems[9]. These data provided the rationale for a recent phase II clinical trial of RT, TMZ, and enzastaurin in patients with newly diagnosed GBM. Although the clinical outcome data intended for patients from this study have already been reported[3], the role of advanced imaging parameters in assessing efficacy and predicting outcome has not yet been presented. Another agent of interest intended for combination therapy is bevacizumab, which is a humanized monoclonal vascular endothelial growth factor (VEGF)blocking antibody that normalizes vascular permeability and regulates angiogenesis[10]. Preliminary studies of bevacizumab in patients with recurrent GBM have shown a dramatic decrease in the size of the enhancing lesion and an increase in progression-free survival (PFS)[11],[12],[13]. This led to a number of clinical trials of patients with GBM that combined bevacizumab with standard RT and chemotherapy. The biological hypotheses that have driven these analyses are that combination treatment would normalize tortuous tumor vasculature, improve the delivery of chemotherapeutics, and hence provide improved overall survival[14]. The disadvantage of treatments such as enzastaurin and bevacizumab is that they cause changes in anatomic imaging characteristics, which can make it difficult to use conventional methods for assessing response to therapy. For example , brokers that reduce proliferation may result in a clinical assessment of stable disease, whereas antiangiogenic agents decrease the size of the contrast-enhancing lesion (CEL), but this does not necessarily signify a reduction in bulk tumor[11]. Another complication of anti-VEGF brokers that have been reported is to result in increased tumor invasiveness that is expressed by an increase in Gabazine the size of the region of T2 hyperintensity rather than the changes in the enhancing lesions[15]. Although the Response Assessment in Neuro-Oncology criteria include consideration of changes in the T2 lesion as part of the definition of response to therapy[16], it is not clear whether such changes are specific Gabazine to recurrent tumor or represent nonspecific RT-induced changes in normal white matter. Diffusion-weighted imaging has been proposed as an adjunct to standard anatomic imaging because it can provide new information about response to therapy through the evaluation of parametric images that reflect variations in tissue composition and architecture[17],[18],[19]. The most widely Gabazine considered variable is the apparent diffusion coefficient (ADC), which is sensitive to an increase in tumor cellularity, formation of necrosis, and the presence of vasogenic edema. Other variables of interest are the fractional anisotropy (FA), which describes variability in the directionality of diffusion, and eigenvalues (EV1 and EVrad), which provide information on the magnitude of the preferred (longitudinal) direction of diffusion and.